Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.18 | 17.67 | 23.00 | 19.43 | 29.15 | 25.39 | 22.50 | 22.23 | 33.90 | 50.35 | 35.43 | 33.49 |
| Expenses | 11.39 | 8.80 | 13.12 | 8.48 | 12.98 | 10.32 | 14.58 | 10.40 | 19.17 | 28.63 | 26.94 | 24.97 |
| Operating Profit | 7.79 | 8.87 | 9.88 | 10.95 | 16.17 | 15.07 | 7.92 | 11.83 | 14.73 | 21.72 | 8.49 | 8.52 |
| OPM % | 40.62% | 50.20% | 42.96% | 56.36% | 55.47% | 59.35% | 35.20% | 53.22% | 43.45% | 43.14% | 23.96% | 25.44% |
| Other Income | 2.75 | 2.63 | 4.19 | 3.69 | 3.44 | 3.01 | 4.94 | 4.32 | 5.51 | 5.59 | 10.15 | 6.14 |
| Interest | 0.04 | 0.03 | 0.04 | 0.01 | 0.03 | 0.02 | 0.04 | 0.01 | 0.04 | 0.09 | 0.10 | 0.10 |
| Depreciation | 0.24 | 0.32 | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.28 | 0.58 | 0.38 | 3.89 | 1.34 |
| Profit before tax | 10.26 | 11.15 | 13.73 | 14.36 | 19.31 | 17.79 | 12.54 | 15.86 | 19.62 | 26.84 | 14.65 | 13.22 |
| Tax % | 26.02% | 23.68% | 35.98% | 21.31% | 22.99% | 24.17% | 35.89% | 20.30% | 23.34% | 16.39% | 33.11% | 32.07% |
| Net Profit | 7.58 | 8.51 | 8.79 | 11.30 | 14.87 | 13.49 | 8.04 | 12.65 | 15.04 | 22.44 | 9.81 | 8.98 |
| EPS in Rs | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 | 11.14 | 11.10 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 142 | 153 |
| Expenses | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 85 | 100 |
| Operating Profit | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 57 | 53 |
| OPM % | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 40% | 35% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 26 | 27 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 |
| Profit before tax | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 77 | 74 |
| Tax % | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | 22% | |
| Net Profit | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 60 | 56 |
| EPS in Rs | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 68.27 | 64.70 |
| Dividend Payout % | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% | 7% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 23% | -9% | 32% | 54% | ||
| Compounded Profit Growth | 68% | -12% | 31% | 13% | ||
| Stock Price CAGR | 60% | 29% | 27% | 16% | ||
| Return on Equity | 27% | 18% | 18% | 20% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 316 |
| Borrowings | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 3 |
| Other Liabilities | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 51 |
| Total Liabilities | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| Fixed Assets | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 158 |
| Other Assets | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 193 |
| Total Assets | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 |
| Cash from Investing Activity | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | -24 |
| Cash from Financing Activity | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 |
| Net Cash Flow | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 | 28 |
| Free Cash Flow | 0 | 1 | 0 | 1 | 3 | 6 | 96 | 35 | 18 | 26 | 42 | 27 |
| CFO/OP | 23% | 69% | 36% | 52% | 71% | 101% | 90% | 129% | 100% | 115% | 116% | 121% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 | 129 |
| Inventory Days | 145 | 143 | 175 | 164 | 141 | 124 | 187 | |||||
| Days Payable | 218 | 203 | 186 | 69 | 66 | 28 | 70 | |||||
| Cash Conversion Cycle | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 | 245 |
| Working Capital Days | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 | 143 |
| ROCE % | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% | 25% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 38.43% | 38.43% | 41.29% | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.27% | 40.94% | 40.95% |
| FIIs | 3.16% | 3.38% | 2.97% | 3.28% | 3.27% | 2.68% | 2.49% | 2.70% | 2.64% | 2.57% | 2.57% | 2.50% |
| DIIs | 0.82% | 1.18% | 1.89% | 1.96% | 1.96% | 1.74% | 1.60% | 1.76% | 1.82% | 1.87% | 1.98% | 2.15% |
| Public | 57.60% | 56.99% | 53.85% | 53.48% | 53.48% | 54.29% | 54.64% | 54.28% | 54.26% | 54.27% | 54.50% | 54.40% |
| No. of Shareholders | 10,513 | 10,088 | 9,753 | 9,399 | 9,586 | 10,166 | 10,345 | 10,619 | 10,709 | 10,507 | 10,616 | 11,049 |
Fundamentals
Market Cap₹ 1,396 Cr.
Current Price₹ 1,623
Stock P/E25.1
Book Value₹ 378
ROCE25.5 %
ROE19.8 %
Dividend Yield0.31 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)54%
Compounded Profit Growth (TTM)13%
Consolidated figures.
Valuation
Market capRs 1,417 Cr
Enterprise valueRs 1,319 Cr
P/E (TTM)25.52x
Price to book4.37x
Price to sales9.25x
EV / EBITDA16.32x
EV / EBIT17.67x
EV / sales8.61x
Price to cash flow27.00x
Earnings yield3.92%
Dividend yield0.30%
P/E, 3-year average24.84x
P/B, 3-year average4.07x
P/E, 5-year average17.85x
P/B, 5-year average2.91x
Profitability
Operating margin (excl. other income)40.01%
Operating margin (incl. other income)58.02%
EBITDA margin52.78%
Pre-tax margin48.53%
Net profit margin36.25%
Net margin, latest quarter28.46%
ROE19.77%
ROCE25.90%
ROA17.39%
ROE, 3-year average18.20%
ROCE, 3-year average24.38%
ROA, 3-year average16.27%
ROE, 5-year average18.43%
ROCE, 5-year average24.66%
ROA, 5-year average15.66%
ROIC (approx.)25.62%
Tax rate22.14%
Other income / net worth7.88%
Growth
Sales growth (latest year)47.11%
Profit growth (latest year)22.86%
Sales CAGR, 3 years31.90%
Sales CAGR, 5 years-8.95%
Profit CAGR, 3 years31.21%
Profit CAGR, 5 years-12.44%
Sales growth QoQ-5.48%
Profit growth QoQ-0.31%
Sales growth YoY (latest quarter)50.65%
Profit growth YoY (latest quarter)-24.30%
Per share
EPS (TTM)Rs 64.54
EPS (latest quarter)Rs 11.08
EPS, 3-year averageRs 46.48
EPS, 5-year averageRs 41.52
Book value per shareRs 377.02
Sales per shareRs 178.03
Cash flow per shareRs 61.00
Free cash flow per shareRs 31.38
Dividend per share, 3-year averageRs 3.50
Dividend per share, 5-year averageRs 4.99
Dividends
Dividend payout7.30%
Dividend payout, 3-year average7.50%
Dividend payout, 5-year average11.03%
Efficiency
Asset turnover0.38x
Fixed asset turnover5.14x
Inventory turnover1.95x
Inventory days187 days
Debtor days129 days
Debtors turnover2.83x
Creditor days70 days
Cash conversion cycle245 days
Working capital days143 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 101 Cr
Net debtRs -98 Cr
Debt to equity0.01x
Net debt / EBITDA-1.21x
Interest coverage226.24x
Owners' fund to total sources85.81%
Debt to assets0.82%
Cash flow
Cash from Operating Activity (latest year)Rs 52 Cr
Cash from Investing Activity (latest year)Rs -24 Cr
Cash from Financing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs 28 Cr
Free cash flow (latest year)Rs 27 Cr
FCFE (approx.: FCF + change in debt)Rs 30 Cr
Cash from ops / profit, 5 years0.90x
Sales to cash flow2.70x
Statement figures
Net sales (TTM)Rs 153 Cr
Net sales (latest year)Rs 142 Cr
Sales (latest quarter)Rs 33 Cr
Operating profit excl. other income (latest year)Rs 57 Cr
Operating profit (latest quarter)Rs 9 Cr
Other income (TTM)Rs 27 Cr
EBITDA (TTM)Rs 81 Cr
PBDT (TTM)Rs 81 Cr
Profit before tax (TTM)Rs 74 Cr
Tax (latest year)Rs 17 Cr
Net profit (TTM)Rs 56 Cr
Net profit (latest year)Rs 59 Cr
Net profit (latest quarter)Rs 10 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 36 Cr
Total expenditure (latest year)Rs 85 Cr
Total income (latest year)Rs 167 Cr
Share capitalRs 9 Cr
ReservesRs 316 Cr
Shareholders' fundsRs 324 Cr
Total assetsRs 378 Cr
Net blockRs 28 Cr
InvestmentsRs 158 Cr
ReceivablesRs 50 Cr
InventoryRs 18 Cr
Other liabilitiesRs 51 Cr
Shares outstanding (crore)0.86
Ownership
Promoter holding40.95% (-0.33 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 25.4 is at the 55th percentile of its own 9.4-year range
(median 23.7, low 2.6, high 129.8).
P/B 4.36 is at the 60th percentile (median 3.92).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 3BBLACKBIO | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +17.1% | -2.8% | +19.9 pts |
| 1 month | +8.1% | -6.8% | +14.9 pts |
| 3 months | +40.3% | -7.6% | +48.0 pts |
| 3 years | +109.6% | +14.2% | +95.4 pts |
| 5 years | +256.3% | +27.9% | +228.4 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 0 bought more and 1 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.04% | 0 | -15% |
Red flags
F-score 4 of 8| look | Inventory outrunning sales Inventory grew 110% vs sales +47% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹33 Cr +50.7% vs Jun 2025.
Net profit ₹9 Cr -29.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32,737 | 58.2 | 28.0 % |
| Vijaya Diagnostic Centre Ltd | 15,192 | 81.0 | 20.5 % |
| Metropolis Healthcare Ltd | 11,665 | 56.0 | 17.8 % |
| Thyrocare Technologies Ltd | 8,708 | 48.2 | 35.4 % |
| Nephrocare Health Services Ltd | 6,671 | 78.4 | 15.3 % |
| Suraksha Diagnostic Ltd | 1,847 | 51.6 | 17.3 % |
| Krsnaa Diagnostics Ltd | 1,791 | 18.1 | 12.7 % |
| One Global Service Provider Ltd | 1,046 | 14.1 | 87.0 % |
| Health X Platform Ltd | 923 | 0.03 % | |
| Gaudium IVF and Women Health Ltd | 830 | 35.9 | 29.3 % |
| Chandan Healthcare Ltd | 581 | 22.1 | 23.3 % |
| Pramodini Medicare Ltd | 259 | 14.9 | 41.8 % |
| Aspira Pathlab & Diagnostics Ltd | 148 | 2.84 % | |
| Choksi Laboratories Ltd | 132 | 69.2 | 9.44 % |
| Star Imaging and Path Lab Ltd | 131 | 6.80 | 26.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-22 | Dividend - Rs 5 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 25perc in previous 15 Days
Quick answers
What is the market cap of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd (3BBLACKBIO) has a market capitalisation of Rs 1,396 Cr. at the 2026-10-01 close.
What is the P/E ratio of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd trades at a P/E of 25.1 on trailing twelve-month profit, at the 2026-10-01 close.
What were 3B Blackbio DX Ltd's latest quarterly results?
In the Jun 2026 quarter, 3B Blackbio DX Ltd sales was Rs 33 Cr (+50.7% vs Jun 2025) and net profit was Rs 9 Cr.
What is the 52-week high and low of 3B Blackbio DX Ltd?
The 52-week high is Rs 1,740.00 and the 52-week low is Rs 1,085.00.